Sea urchins are small and spiny, they have no eyes and they eat kelp and algae. Still, the sea creature?s genome is remarkably similar to humans? and may hold the key to preventing and curing several human diseases, according to a University of Central Florida researcher and several colleagues.
Thanks to a University of Houston scientist and his team’s research, the chemical element germanium is enjoying a rebound in popularity. Led by Arnold Guloy, a UH chemistry professor, and a team of researchers from UH and the Max Planck Institute for Chemical Physics of Solids in Dresden, Germany, the findings are described in a paper titled “A Guest-free Germanium Clathrate” published in Nature magazine.
Your brain may be determining what car you buy before you’ve even taken a test drive. A new study gauging the brain’s response to product branding has found that strong brands elicit strong activity in our brains. The findings were presented today at the annual meeting of the Radiological Society of North America.
GE Healthcare, a unit of General Electric Company (NYSE:GE), today kicked off its participation in the 2006 Radiological Society of North America (RSNA) conference in Chicago with a focus on the company?s ‘Radiology Re-imagined’ theme along prominent displays of breakthough products that highlight the company?s exhibit booth.
A gene variant that increases the risk of developing the aggressive “wet” form of age-related macular degeneration, the most common cause of blindness in people over age 50, is reported in two recent articles in Science by researchers at Yale School of Medicine.
Hearty feasts and couch-potato marathons are holiday traditions, but UT Southwestern Medical Center experts warn that packing on pounds and not exercising could be deadly for the 6 million Americans who have diabetes and don’t even know it.
The Department of Health warns consumers not to buy or use six brands of health products that contain acetildenafil, which can cause side effects.
Pledging his eyes, Health Minister Anbumani Ramadoss today said that the country India hoped to achieve its target of vision to all by the year 2015.
A combined analysis of two landmark clinical glaucoma trials — the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS) — confirms the benefit of a five-year risk assessment model to help ophthalmologists better predict which patients have an increased risk of developing glaucoma. Glaucoma is the second leading cause of blindness in the world, affecting approximately 70 million people, and can lead to blindness if left untreated. These new data were presented this week at the annual American Academy of Ophthalmology meeting.
Novartis has received a positive opinion supporting European Union regulatory approval for Lucentis? (ranibizumab) as a new treatment option for patients with the “wet” form of age-related macular degeneration, the leading cause of severe vision loss in people over age 50 in the western world.